As Director of Partnerships & Scientific Strategy for ADDI, Matt develops relationships with new partners, subject matter experts, and key opinion leaders to enable researchers to accelerate progress toward new treatments for Alzheimer’s and related dementias through ADDI’s data platform, the AD Workbench. Prior to preparations for ADDI’s launch in 2020, Matt worked as a consultant for organizations funding research and development activities in the philanthropic and US government sectors. His previous roles have been centered on strategic planning, program management, stakeholder engagement, source selection and proposal evaluation, and scientific writing. Matt’s past work has focused on a range of subject areas including microbial metabolism and genetics, biomarker discovery, assay and diagnostic development, neurodegenerative disease, and biological agent surveillance and detection. Matt earned his PhD in Biochemistry and Molecular Biology from the University of California, Los Angeles and received a BA in Chemistry from Macalester College in the US.

After graduating from the University of Konstanz, Germany with a MSc in Medical Biology, Verena moved on to work at the Max-Delbrück Center for Molecular Medicine in the Helmholtz Association in Berlin, Germany, where she received her PhD in Neuroimmunology, focusing on the identification of markers that distinguish microglia from infiltrating monocytes in health and disease. In the early beginnings of the Covid-19 pandemic, she worked as a Postdoc at the Institute of Virology at the Charité in Berlin, Germany, focusing on the evaluation of rapid antigen tests for SARS-CoV-2. Since 2021, she is a Postdoctoral fellow at the Center for Translational and Computational Neuroimmunology at Columbia University in New York City, USA. Her work focuses on the heterogeneity of human microglia as well as the development of in vitro models of human microglia in order to further study the function of recently identified microglial subclusters.

I am Research Director in Molecular Neurodegeneration at the A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland, and an active member of the Finnish FinFTD Research network. I hold MSc in biotechnology and PhD in neurobiology. The research focus of my group lies on the genetic background, new biomarkers, and molecular basis of neurodegeneration in frontotemporal dementia (FTD). We utilize patient-derived skin fibroblasts and induced pluripotent stem cell-derived neurons and microglia, and brain, blood, and cerebrospinal fluid samples from FTD patients and different molecular, cell biological, and biochemical methods in our research.

Dr. Haass graduated in Molecular Biology at the University of Heidelberg, Germany. He was a postdoc and assistant professor of Neurology at the Harvard Medical School in the institute of Dr. Dennis Selkoe. He was appointed as professor at the Central Institute of Mental Health in Mannheim in 1995. Since 1999 he is the head of the division of Biochemistry at the Ludwig-Maximilians-University and since 2009 he is also the speaker of the German Center for Neurodegenerative Diseases (DZNE) in Munich. Since 2012, he is speaker of the DFG Excellence Cluster "Systems Neurology" (SyNergy). Dr. Haass was member of the senate of the Deutsche Forschungsgemeinschaft (DFG) and he is elected member of the European Molecular Biology Organization (EMBO), the Leopoldina and the Bavarian Academy of Sciences and Humanities. He has received a number of prestigious awards, among them the Gottfried Wilhelm Leibniz-Award of the Deutsche Forschungsgemeinschaft, the Potamkin Award of the American Academy of Neurology, the ERC advanced grant, a Honorary Degree of the University of Zurich, the Order of Merrit on Ribbon from the Federal Republic of Germany, the MetLife Foundation Award for Medical Research and the Brain Prize.

After studying Biology at the universities of Constance and Freiburg in Germany, I received my doctoral degree in clinical-oriented neuroscience in Bern, Switzerland, in December 2020. As a postdoc at the University Hospital of Psychiatry and Psychotherapy Bern, I am continuing this interdisciplinary line of research. A collaboration of my institute in Switzerland with the Karolinska Institute brought me to Stockholm, Sweden, in May 2021. My research revolves around neural and cognitive networks in healthy ageing and neurodegenerative disorders, with a current focus on DLB. My systematic review on connectivity studies in DLB (“Disconnected Dots in Dementia with Lewy Bodies – a Systematic Review of Connectivity Studies”) was recently published in Movement Disorders. Additionally, I am involved in DLB networks of a different kind, being the current postdoc executive committee member of the LBD PIA and co-organising the next NextGen DLB webinar.

I am an Associate Professor in molecular epidemiology with a research interest in human biological aging. I am leading a research group in aging epidemiology at Karolinska Institutet in Stockholm. I use large-scale data to study markers of biological aging, associations with age-related diseases and identify drugs to repurpose for Alzheimer´s disease and other related traits.

Raza Haider joined Case Western Reserve University's MD/PhD program in 2016, and is currently a 5th year graduate student in the lab of Dr. Witold Surewicz. His work centers examining the liquid-liquid phase separation and aggregation of intrinsically disordered proteins involved in neurodegeneration, with a focus on how phosphorylation affects these behaviors. While working on his PhD, Raza has secured a F31 fellowship to fund his projects, co-authored a book chapter on the role of liquid-liquid phase separation in neurodegenerative diseases, and delivered lectures to medical and undergraduate students about his field of study in order to sharpen his skills in multiple areas. He hopes eventually to pursue a career as a physician-scientist in the field of neurology.

Accomplished neurophysiologist with internationally recognized expertise in neurobiology and pharmacology of psychiatric and neurological disorders; extensive research experience and leadership in both academic and industrial drug discovery. Thought leader in translational medicine and CNS biomarkers. Currently Chief Scientific Officer at Cognito Therapeutics, and Professor Adjunct at Yale University School of Medicine.

I received my Bachelor’s degree from University of California, Davis with Neurobiology, Physiology, and Behavior major. I currently work as a Junior Specialist at University of California Davis School of Medicine Department of Neurology. The focus of my research involves biomarkers and gene expression of neurological diseases.

Dr Hamilton is a postdoctoral researcher at Newcastle University with a background in cognitive psychology. He has an interest in disease progression in Lewy body disease and Alzheimer's disease, and in understanding how and why individuals with the same diagnosis might differ in their respective prognosis.

Dr. Hampel, serves as Chief Medical Officer, Senior Vice President, Neurology Business Group, Eisai Inc. As CMO, Dr. Hampel is responsible for leading Eisai’s medical affairs strategy and providing scientific and medical expertise in neurology with the aim of developing targeted solutions to prevent and treat neurological conditions. Dr. Hampel provides executive direction and medical guidance in the planning and implementation of Eisai’s global therapeutic pipeline which includes Alzheimer’s disease, dementia disorders, Epilepsy and sleep/wake disorders. He is also responsible for developing the global neurology medical affairs strategies for the company’s commercial products, pipeline assets and late-stage compounds approaching the commercialization stage. Prior to joining Eisai, Dr. Hampel served as Professor of Neurology at Sorbonne University in Paris; Professor, Head of Department of Psychiatry, University of Frankfurt; Professor and Chair of Psychiatry at Trinity College, University of Dublin; Professor at the University of Munich; Postdoctoral fellowship at the NIH, Bethesda. Dr. Hampel has authored more than 800 scientific publications focused on AD. He is the founding president of the Alzheimer Precision Medicine Initiative, and is Senior Associate Editor of Alzheimer's & Dementia, the journal of the Alzheimer’s Association. He has won numerous awards and holds 10 patents for his research.